Merck (NYSE:MRK) received FDA approval for expanded use of KEYTRUDA and KEYTRUDA QLEX with WELIREG as adjuvant treatment in ...

Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

The approvals are based on data from the pivotal Phase III LITESPARK-022 trial, which enrolled 1,841 patients.

Merck & Co., Inc. (NYSE:MRK) is one of Kevin O’Leary’s top stock picks for 2026 through the O’Shares U.S. Quality Dividend ...

In Q1, revenue of Merck's oncology unit rose 9.6% year-over-year to about $8.8 billion. And in my opinion, the key ...

Regulatory clearance includes IV pembrolizumab and subcutaneous pembrolizumab/berahyaluronidase with belzutifan for adjuvant treatment after nephrectomy, including ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

The US Food and Drug Administration (FDA) announced Tuesday that it has limited the use of Roche’s Tecentriq (atezolizumab) and Merck’s Keytruda (pembrolizumab) for patients with locally advanced or ...

What Is It, and Why Does It Matter? The FDA has approved a new combination therapy for adults with epithelial cancers that start in the ovaries, fallopian tubes, or lining of the abdomen (peritoneum).